Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson's Disease
Observational studyHumans
- Design
- Observational study
- Subjects
- 30 patients with Parkinson's disease already taking levodopa
- Dose used in the study
- 600 mg of ultramicronised palmitoylethanolamide, added to usual treatment
- Duration
- One year
- What was measured
- The MDS-UPDRS rating scale for motor and non-motor symptoms, before and during treatment
What the authors reported
The authors reported a significant and progressive fall in the total rating scale score over the year, with a reduction in most motor and non-motor symptoms. No participant reported side effects attributed to the supplement.
Limits of this study
A before-and-after study of 30 patients with no control group and no blinding. Rating scale scores in Parkinson's disease respond to expectation and to changes in other medication. The entry was checked against the abstract only.
Source
doi:10.2174/1871527316666170321124949
Entry checked against the abstract page at the publisher (Bentham Science) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.